Sandra Wainwright, MD
Pulmonary Disease · Norwalk, CTNPI 1982894614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Sechrist Industries Inc at 28.7% of the total. Reporting peaked in 2022 at $152 and has fallen 90.0% since, to $15 in 2025. That places this record below the midpoint for pulmonary disease clinicians in CT, where the typical reported total is $1,017.
Across 13 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sechrist Industries Inc$90
- Convatec Inc.$65
- Kerecis Limited$34
- Smith+Nephew$28
- Next Science LLC$28
- Solventum Corporation$23
- plus $46 from 3 others
What the payments were for
- Food & beverage$314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sechrist Industries Inc | 1 | $90 |
| Convatec Inc. | 3 | $65 |
| Kerecis Limited | 1 | $34 |
| Smith+Nephew | 1 | $28 |
| Next Science LLC | 2 | $28 |
| Solventum Corporation | 1 | $23 |
| Medela LLC | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $19 |
| Organogenesis Inc. | 2 | $7 |
How this compares
$314 in reported general payments places this provider in the 30th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 34 | $1,351 |
| Doxycycline Hyclate | 58 | $783 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 23 | $408 |
| Silver Sulfadiazine | 11 | $273 |
| Gabapentin | 24 | $255 |
| Ammonium Lactate | 15 | $254 |
| Ciprofloxacin Hcl | 30 | $250 |
| Mupirocin | 32 | $228 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $141 |
| Tramadol Hcl | 14 | $119 |
| Ketoconazole | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Norwalk
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.